FDA Greenlights Bladder Cancer Drug, RPRX Up 30% After-hours, Mega Leap For MGNX

Shares of Repros Therapeutics Inc. (RPRX) were up over 30% in extended trading on Wednesday, following positive results from a phase 2b study of oral Proellex in women with severe menstrual bleeding due to uterine fibroids.

from RTT - Biotech http://ift.tt/27BQiXw
via IFTTT